Want to see HRMY full AI Analyst Report?
Total Valuation
Harmony Biosciences Holdings has a market cap or net worth of $2.04B. The enterprise value is $1.21K.
Market Cap$2.04B
Enterprise Value$1.21K
Share Statistics
Harmony Biosciences Holdings has 57,892,677 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,892,677
Owned by Insiders1.11%
Owned by Institutions5.70%
Financial Efficiency
Harmony Biosciences Holdings’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 13.90%.
Return on Equity (ROE)0.18
Return on Assets (ROA)0.12
Return on Invested Capital (ROIC)13.90%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee2.96M
Profits Per Employee0.00
Employee Count293
Asset Turnover0.68
Inventory Turnover37.02
Valuation Ratios
The current PE Ratio of Harmony Biosciences Holdings is 14.0. Harmony Biosciences Holdings’s PEG ratio is 1.74.
PE Ratio14.0
PS Ratio2.48
PB Ratio2.47
Price to Fair Value2.47
Price to FCF6.18
Price to Operating Cash Flow6.26
PEG Ratio1.74
Income Statement
In the last 12 months, Harmony Biosciences Holdings had revenue of 868.45M and earned 158.69M in profits. Earnings per share was 2.76.
Revenue868.45M
Gross Profit670.11M
Operating Income208.47M
Pretax Income215.06M
Net Income158.69M
EBITDA255.05M
Earnings Per Share (EPS)2.76
Cash Flow
In the last 12 months, operating cash flow was 355.08M and capital expenditures -178.00K, giving a free cash flow of 354.90M billion.
Operating Cash Flow355.08M
Free Cash Flow354.90M
Free Cash Flow per Share6.13
Dividends & Yields
Harmony Biosciences Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.02
52-Week Price Change10.37%
50-Day Moving Average35.04
200-Day Moving Average33.34
Relative Strength Index (RSI)61.36
Average Volume (3m)836.22K
Important Dates
Harmony Biosciences Holdings upcoming earnings date is Nov 3, 2026, Before Open (Confirmed).
Last Earnings DateAug 4, 2026
Next Earnings DateNov 3, 2026
Ex-Dividend Date―
Financial Position
Harmony Biosciences Holdings as a current ratio of 3.60, with Debt / Equity ratio of 15.41%
Current Ratio3.60
Quick Ratio3.58
Debt to Market Cap0.11
Net Debt to EBITDA-2.01
Interest Coverage Ratio14.23
Taxes
In the past 12 months, Harmony Biosciences Holdings has paid 56.38M in taxes.
Income Tax56.38M
Effective Tax Rate0.26
Enterprise Valuation
Harmony Biosciences Holdings EV to EBITDA ratio is 6.42, with an EV/FCF ratio of 4.71.
EV to Sales1.89
EV to EBITDA6.42
EV to Free Cash Flow4.71
EV to Operating Cash Flow4.71
Balance Sheet
Harmony Biosciences Holdings has $667.79M in cash and marketable securities with $153.96M in debt, giving a net cash position of $513.83M billion.
Cash & Marketable Securities$667.79M
Total Debt$153.96M
Net Cash$513.83M
Net Cash Per Share$8.88
Tangible Book Value Per Share$13.58
Margins
Gross margin is 75.42%, with operating margin of 24.00%, and net profit margin of 18.27%.
Gross Margin75.42%
Operating Margin24.00%
Pretax Margin24.76%
Net Profit Margin18.27%
EBITDA Margin29.37%
EBIT Margin26.45%
Analyst Forecast
The average price target for Harmony Biosciences Holdings is $42.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$42.29
Price Target Upside19.72% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast20.71%
EPS Growth Forecast-5.53%